GLP-1 Weight-Loss Drugs: Expert Risks & Clinical Evidence
GLP-1 weight loss risks include dose-dependent side effects such as nausea and pancreatitis. Understanding clinical evidence is essential for safe use of GLP-1 receptor agonists. Proper monitoring improves patient outcomes and medication adherence.
Walmart Pharmacy Expands GLP-1 Weight Loss Programs
Walmart Pharmacy has expanded its GLP-1 weight loss programs, improving patient access to these therapies. The Medicare GLP-1 Bridge program helps bridge coverage gaps for eligible patients. These retail pharmacy programs represent a shift in how…
GLP-1 Weight Loss Cardiovascular Evidence: What Trials Show
Tirzepatide cardiovascular safety is a critical focus in recent clinical trials evaluating GLP-1 weight loss therapies. These studies provide evidence on cardiovascular outcomes alongside weight management benefits. Understanding tirzepatide's safety…
GLP-1 Receptor Agonist: Wegovy Access at $399/Month
Wegovy access offers a transparent $399 monthly self-pay option for FDA-approved GLP-1 receptor agonist therapy. This pricing reduces cost barriers for patients managing obesity. Clinicians can now counsel patients more effectively on affordable…
Daily Cannabis Use and Moderate-to-Severe Use Disorder Risk in Primary Care
Cannabis use disorder prevalence increases with frequency of use, especially among daily users in primary care. This study highlights a 1-in-5 chance of moderate-to-severe disorder among daily cannabis users. Understanding cannabis use disorder…
Patients Report Lower Satisfaction at Medicinal Cannabis Clinics vs General Practice
A 2025 Australian survey reveals patient satisfaction medicinal cannabis clinics is lower than in general practice settings. Patients reported less satisfaction with consultation time, information on risks and benefits, and treatment integration. These…
Thousands in Hampshire Using Medical Cannabis, Figures Show – Daily Echo
Medical cannabis usage in Hampshire is rising, with thousands of residents reported using it. This data highlights regional patterns important for clinicians. Understanding these trends helps improve patient care and prescribing practices.
Eli Lilly’s Oral GLP-1 Therapy Now Sold on Amazon
Oral GLP-1 therapy is transforming weight management with Eli Lilly’s new pill available on Amazon. This direct-to-consumer approach allows patients easier access but requires careful clinical oversight. Family physicians should integrate oral GLP-1…
Avoiding the Biggest Clinical Mistakes in GLP-1 Receptor Agonist Use
GLP-1 receptor agonist clinical mistakes often reduce treatment effectiveness and safety. Patients frequently discontinue therapy prematurely or mismanage dosing. Recognizing and addressing these errors is essential for optimal weight management outcomes.
Clinical Evidence on Dietary Fiber and GLP-1 Receptor Agonists
Dietary fiber GLP-1 receptor agonist effects are emerging as a complementary approach in metabolic health. This evidence highlights the potential role of fermentable fibers in appetite regulation. Family medicine clinicians should consider dietary fiber…